Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines nonmalignant skin toxicities from immunosuppressive and transplant-related medications, emphasizing the need for effective identification and management by care providers; it presents no new research findings.

This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.

This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.

This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.

This study investigated paternal drug exposure using FDA data and identified significant associations with reproductive health risks, including congenital anomalies linked to immunosuppressive drugs, and emphasized specific risk combinations like biologics and abortion, diazepam and small for date baby, and finasteride and cryptorchidism.